Coming Down the Pike: Chaperones - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Coming Down the Pike: Chaperones


Pharmaceutical Technology
Volume 32, Issue 11, pp. 24

The analogy is often made comparing proteins with machines. It's an apt analogy, and like a bent or twisted machine, a misshapen protein is unable to function properly. Proteins are long chains of amino acids, folded into a certain configuration that allows them to perform a mechanical function. When they're folded incorrectly, they perform that function poorly or not at all, and that malfunction can lead to disease.

In humans, for example, misfolded proteins lay at the heart of diseases such as phenylketonuria (PKU) and cystic fibrosis. Many of these diseases have genetic origins, and much research has focused on correcting the gene. An alternative approach may be to look for an agent that can restore a protein to its proper shape. This approach might, in theory, also restore the protein's function.

Indeed, in nature, molecules called "chaperones" facilitate correct protein folding. Angel Pey and colleagues at the University of Bergen in Norway, the Universidad de Zaragoza in Spain, the Biocomputation and Complex Systems Physics Institute also in Zaragoza, and the University of Zurich in Switzerland, tested a panel of chemicals to see whether any would act like chaperones and restore the shape and function of the protein phenylalanine hydroxylase (PAH), the protein when misfolded leads to PKU.

In a report in the Journal of Clinical Investigation, the team reports that several chemicals showed evidence of improving activity in animal models. It remains to be seen whether these particular compounds can be developed into drugs. But the larger message for drug developers is that it may be worthwhile to look for drugs with chaperone-like activity when trying to reverse the symptoms of genetically determined diseases.

Source: A.L. Pey et al., "Identification of Pharmacological Chaperones as Potential Therapeutic Agents to Treat Phenylketonuria," Jrnl. of Clin. Invest. 118, 2858–2867 (2008).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here